About LUNAC Therapeutics

At LUNAC Therapeutics we're developing a first-in-class, next generation oral anticoagulant for the treatment and prevention of life-threatening thrombotic events, without the bleeding risk associated with current anticoagulants.

Our focus is on the inhibition of activated Factor XII (FXIIa), a clotting factor enzyme which plays a key role in pathological clot formation (thrombosis) but not in the stemming of bleeding (haemostasis).

LUNAC is a spin-out company from the University of Leeds, founded and supported by world-leading experts in blood coagulation. 

 

Professor Helen Philippou

Helen Philippou is Professor of Translational Medicine in the Faculty of Medicine and Health at the University of Leeds. She is a world-leading researcher on the blood coagulation cascade, with >60 peer reviewed publications in high impact journal and 3 published patents. Helen serves on the Editorial Board of the RPTH Journal, is the Scientific Secretary for the British Society of Haemostasis and Thrombosis Society Committee (since 2016), and is a Co-Chair for the FXI and Contact System SSC of the International Society of Thrombosis and Haemostasis (ISTH). 

Dr. Richard Foster

Dr Richard Foster is an Associate Professor at the University of Leeds. He directs a large, multidisciplinary team in the area of small molecule hit identification and optimisation. Prior to joining the University of Leeds, Richard was a senior research manager at Tripos Discovery Research where he led medicinal chemistry efforts directed at cardiovascular, metabolic, inflammatory and CNS disorders. Richard has co-authored over 60 peer-reviewed publications and patents.

   SCIENTIFIC FOUNDERS   

Our Science

Oral anticoagulants are life-saving drugs which are significantly under-utilised because of the difficulty of balancing anti-thrombotic activity with risk of major bleeding. All current anticoagulants target parts of the coagulation cascade which are essential for normal blood clotting.

 

LUNAC Therapeutics is taking a different approach; our first-in-class oral small molecule targets activated Factor XII (FXIIa), a coagulation factor enzyme that plays a key role in pathological occlusive clot formation but not in the normal stemming of bleeding.

 
 

Our People

Dr_Mervyn_Turner.jpg

Dr. Mervyn Turner 

CHAIRMAN

Prof.Helen_Philippou.jpg

Prof. Helen Philippou

BOARD MEMBER

Dr_Pete_Finan.jpg

Dr. Pete Finan

BOARD MEMBER

Dr_Mary_Canning.jpg

Dr. Mary Canning

BOARD MEMBER

Dr_Sarah_Jarmin.jpg

Dr. Sarah Jarmin

BOARD MEMBER

   THE BOARD   

Mr_Richard_Brooks.jpg

Richard Brooks, CA 

HEAD OF FINANCE 

Dr_Alan_Naylor.jpg

Dr. Alan Naylor

ADVISOR

Dr_John_Dixon.jpg

Dr. John Dixon

ADVISOR

view Bio 

Dr_Bob_Humphries.jpg

Dr. Bob Humphries

ADVISOR

   CONSULTANTS & ADVISORS   

 

Epidarex Capital

Epidarex Capital invests in early-stage, high growth life science and health technology Epidarex Capital is a transatlantic venture fund that invests in early-stage, high growth life science and health technology companies in under-ventured markets.

 

Epidarex focuses on providing risk capital to young companies, including spin-outs from leading research institutions in up and coming life science hubs. The firm’s international management team has a track record of successfully partnering with top scientists and entrepreneurs to develop highly innovative products for the global healthcare market.

University of Leeds

The University of Leeds has an impressive track record in transforming academic research into commercial success and has created more than 110 spin-out companies since 1995.

more information

   INVESTORS   

Latest News